mRNAプラットフォーム市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、有用性別、mRNAタイプ別、エンドユーザー別、地域別、競合別、2020-2030年

世界のmRNAプラットフォーム市場は2024年に73億米ドルと評価され、2030年までCAGR 3.56％で成長すると予測されています。

mRNA（メッセンジャーRNA）プラットフォームは、合成RNA分子が遺伝的指示を細胞に伝え、特定のタンパク質の産生を促すことを可能にする高度なバイオ技術革新です。このアプローチはワクチン開発で大きな成功を収め、さまざまな疾患の治療へと拡大しつつあります。特に、2023年9月、バイオエヌテックSEはCEPIと提携し、mRNAベースのMpoxワクチンの開発を加速させ、新たな感染症の脅威に備える上でこのプラットフォームの重要性を強調しています。体内におけるRNAの自然な役割を模倣することで、合成mRNA配列は免疫反応を促したり、治療用タンパク質の生産をサポートするように設計されます。これらの技術は、その適応性、開発スピード、有効性から、特に公衆衛生上の緊急事態や個別化医療への応用において、ますます採用されるようになっています。

市場促進要因

技術の進歩

主な市場課題

ワクチン嫌いと誤った情報

主要市場動向

バーチャルトライアルの増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のmRNAプラットフォーム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（自己免疫疾患、がん、感染症、希少疾患、呼吸器疾患）
  • 有用性別（予防ワクチン、治療薬、治療ワクチン）
  • mRNAの種類別（ヌクレオシド修飾mRNA、自己増幅mRNA、非修飾mRNA）
  • エンドユーザー別（病院・クリニック、製薬会社、調査機関）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のmRNAプラットフォーム市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のmRNAプラットフォーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のmRNAプラットフォーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のmRNAプラットフォーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのmRNAプラットフォーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のmRNAプラットフォーム市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Amgen Inc. AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• Baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected to grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules to deliver genetic instructions to cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding into treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.

Key Market Drivers

Technological Advancements

Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development. Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.

Key Market Challenges

Vaccine Hesitancy and Misinformation

A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.

Key Market Trends

Increase in the Number of Virtual Trials

The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.

Key Market Players

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

• Autoimmune Diseases
• Cancer
  • Personalized Treatment
  • Single Cancer Focused
• Infectious Diseases
• Rare Diseases
• Respiratory Diseases

mRNA Platform Market, By Usability:

• Prophylactic Vaccines
• Therapeutic Drugs
• Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

• Nucleoside-Modified mRNA
• Self-Amplifying mRNA
• Unmodified mRNA

mRNA Platform Market, By End-User:

• Hospitals & Clinics
• Pharmaceutical Companies
• Research Organization

mRNA Platform Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
  • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
  • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
  • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Usability
  • 6.2.3. By mRNA Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China mRNA Platform Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Usability
      • 6.3.1.2.3. By mRNA Type
      • 6.3.1.2.4. By End User
  • 6.3.2. India mRNA Platform Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Usability
      • 6.3.2.2.3. By mRNA Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Australia mRNA Platform Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Usability
      • 6.3.3.2.3. By mRNA Type
      • 6.3.3.2.4. By End User
  • 6.3.4. Japan mRNA Platform Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Usability
      • 6.3.4.2.3. By mRNA Type
      • 6.3.4.2.4. By End User
  • 6.3.5. South Korea mRNA Platform Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Usability
      • 6.3.5.2.3. By mRNA Type
      • 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Usability
  • 7.2.3. By mRNA Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France mRNA Platform Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Usability
      • 7.3.1.2.3. By mRNA Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany mRNA Platform Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Usability
      • 7.3.2.2.3. By mRNA Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Spain mRNA Platform Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Usability
      • 7.3.3.2.3. By mRNA Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy mRNA Platform Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Usability
      • 7.3.4.2.3. By mRNA Type
      • 7.3.4.2.4. By End User
  • 7.3.5. United Kingdom mRNA Platform Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Usability
      • 7.3.5.2.3. By mRNA Type
      • 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Usability
  • 8.2.3. By mRNA Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States mRNA Platform Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Usability
      • 8.3.1.2.3. By mRNA Type
      • 8.3.1.2.4. By End User
  • 8.3.2. Mexico mRNA Platform Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Usability
      • 8.3.2.2.3. By mRNA Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Canada mRNA Platform Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Usability
      • 8.3.3.2.3. By mRNA Type
      • 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Usability
  • 9.2.3. By mRNA Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil mRNA Platform Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Usability
      • 9.3.1.2.3. By mRNA Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina mRNA Platform Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Usability
      • 9.3.2.2.3. By mRNA Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia mRNA Platform Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Usability
      • 9.3.3.2.3. By mRNA Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Usability
  • 10.2.3. By mRNA Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa mRNA Platform Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Usability
      • 10.3.1.2.3. By mRNA Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia mRNA Platform Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Usability
      • 10.3.2.2.3. By mRNA Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE mRNA Platform Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Usability
      • 10.3.3.2.3. By mRNA Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Amgen Inc. AstraZeneca PLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Asuragen, Inc.
• 16.3. Catalent Pharma Solutions
• 16.4. Arcturus Therapeutics, Inc.
• 16.5. BioNTech AG
• 16.6. CRISPR Therapeutics Inc.
• 16.7. AKESOgen, Inc.
• 16.8. Baseclick GmbH
• 16.9. Accent Therapeutics Inc.
• 16.10.Accanis Biotech F&E GmbH & Co KG

17. Strategic Recommendations

18. About Us & Disclaimer